The FDA granted tentative approval of Bafiertam on November 16, 2018 under a New Drug Application submitted under the 505(b) (2) filing pathway.
Bafiertam, a novel fumarate bioequivalent alternative to a prodrug of BAFIERTAM, Tecfidera1 (dimethyl fumarate) of Biogen Inc, met the required bioequivalence, safety, efficacy and quality standards for tentative approval.
Final approval was pending the expiration of US Patent Number 7,619,001 on June 20, 2020 protecting Biogen's Tecfidera, or the outcome of pending litigation between Banner and Biogen regarding the patent.
In January 2019, Banner announced that the US District Court for the District of Delaware had ruled in favor of Banner's motion for judgment on the pleadings against Biogen, Inc. deciding Bafiertam does not infringe the '001 patent, thus permitting Banner to seek final FDA approval.
On April 21, 2020, Banner announced that the United States Court of Appeals for the Federal Circuit had upheld the earlier Court's decision.
Bafiertam is a prescription medicine used to treat relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Relapsing-remitting multiple sclerosis, the most common form of MS, is a debilitating autoimmune disease characterized by inflammatory attacks to the central nervous system followed by periods of remission.
RRMS affects approximately 85% of patients diagnosed with MS, or an estimated 2m people worldwide.
There is no cure for MS and disease progression and degree of impairment vary widely by patient depending on the location and extent of nerve damage.
Treatment regimens for RRMS focus on symptom management, slowing disease progression and reducing relapses.
Chemomab secures new patents for CM-101 monoclonal antibody
argenx receives FDA priority review for VYVGART Hytrulo in CIDP
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Ono partners with Shattuck Labs for bifunctional fusion proteins
Artax Biopharma doses first subject in AX-158 Phase 2a psoriasis trial
Innovent Biologics announces CFO transition
Bio-Thera Solutions commences dosing in BAT6026 Phase IA/IIB clinical trial
BioSenic expands patent coverage for ATO therapeutic platform
Celltrion USA submits CT-P47 Biologics License Application to FDA
NS Pharma's NS-229 receives European Commission orphan drug designation
Kyverna Therapeutics' KYV-101 granted US FDA fast track designation
InnoCare Pharma receives U.S. FDA clearance for ICP-248 clinical trial